248 related articles for article (PubMed ID: 25331103)
1. Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer.
Makkouk A; Joshi VB; Wongrakpanich A; Lemke CD; Gross BP; Salem AK; Weiner GJ
AAPS J; 2015 Jan; 17(1):184-93. PubMed ID: 25331103
[TBL] [Abstract][Full Text] [Related]
2. Three steps to breaking immune tolerance to lymphoma: a microparticle approach.
Makkouk A; Joshi VB; Lemke CD; Wongrakpanich A; Olivier AK; Blackwell SE; Salem AK; Weiner GJ
Cancer Immunol Res; 2015 Apr; 3(4):389-98. PubMed ID: 25627654
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained- release inhalation system for the treatment of metastatic lung cancer.
Kim I; Byeon HJ; Kim TH; Lee ES; Oh KT; Shin BS; Lee KC; Youn YS
Biomaterials; 2012 Aug; 33(22):5574-83. PubMed ID: 22579235
[TBL] [Abstract][Full Text] [Related]
4. Combining ultrasound and intratumoral administration of doxorubicin-loaded microspheres to enhance tumor cell killing.
Do AV; Geary SM; Seol D; Tobias P; Carlsen D; Leelakanok N; Martin JA; Salem AK
Int J Pharm; 2018 Mar; 539(1-2):139-146. PubMed ID: 29353083
[TBL] [Abstract][Full Text] [Related]
5. Co-encapsulated CpG oligodeoxynucleotides and ovalbumin in PLGA microparticles; an in vitro and in vivo study.
San Román B; Gómez S; Irache JM; Espuelas S
J Pharm Pharm Sci; 2014; 17(4):541-53. PubMed ID: 25579433
[TBL] [Abstract][Full Text] [Related]
6. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
7. Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice.
Mueller M; Reichardt W; Koerner J; Groettrup M
J Control Release; 2012 Aug; 162(1):159-66. PubMed ID: 22709589
[TBL] [Abstract][Full Text] [Related]
8. The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma.
Pradhan P; Qin H; Leleux JA; Gwak D; Sakamaki I; Kwak LW; Roy K
Biomaterials; 2014 Jul; 35(21):5491-504. PubMed ID: 24720881
[TBL] [Abstract][Full Text] [Related]
9. Delivery of doxorubicin and paclitaxel from double-layered microparticles: The effects of layer thickness and dual-drug vs. single-drug loading.
Lee WL; Guo WM; Ho VHB; Saha A; Chong HC; Tan NS; Tan EY; Loo SCJ
Acta Biomater; 2015 Nov; 27():53-65. PubMed ID: 26340886
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
Zhang XQ; Dahle CE; Weiner GJ; Salem AK
J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736
[TBL] [Abstract][Full Text] [Related]
11. Immunization against leishmaniasis by PLGA nanospheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN.
Tafaghodi M; Khamesipour A; Jaafari MR
Parasitol Res; 2011 May; 108(5):1265-73. PubMed ID: 21125294
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin-loaded porous PLGA microparticles with surface attached TRAIL for the inhalation treatment of metastatic lung cancer.
Kim I; Byeon HJ; Kim TH; Lee ES; Oh KT; Shin BS; Lee KC; Youn YS
Biomaterials; 2013 Sep; 34(27):6444-53. PubMed ID: 23755831
[TBL] [Abstract][Full Text] [Related]
13. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
14. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of a targeted and sustained release system for retinoblastoma cells using Doxorubicin as a model drug.
Boddu SH; Jwala J; Chowdhury MR; Mitra AK
J Ocul Pharmacol Ther; 2010 Oct; 26(5):459-68. PubMed ID: 20874666
[TBL] [Abstract][Full Text] [Related]
16. Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant.
Mueller M; Schlosser E; Gander B; Groettrup M
Int J Cancer; 2011 Jul; 129(2):407-16. PubMed ID: 21207410
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-loaded poly(lactic-co-glycolic acid) microspheres prepared using the solid-in-oil-in-water method for the transarterial chemoembolization of a liver tumor.
Choi JW; Park JH; Baek SY; Kim DD; Kim HC; Cho HJ
Colloids Surf B Biointerfaces; 2015 Aug; 132():305-12. PubMed ID: 26057730
[TBL] [Abstract][Full Text] [Related]
18. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.
Diwan M; Elamanchili P; Cao M; Samuel J
Curr Drug Deliv; 2004 Oct; 1(4):405-12. PubMed ID: 16305402
[TBL] [Abstract][Full Text] [Related]
19. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles.
Zhang XQ; Dahle CE; Baman NK; Rich N; Weiner GJ; Salem AK
J Immunother; 2007; 30(5):469-78. PubMed ID: 17589287
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.
Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J
J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
